Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 11/20 | 0.58 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2997911 | 1.00 | TACR1 (0.58) | TACR1CA1CA2CA7CA9 | |
| SCHEMBL13267636 | 1.00 | TACR1 (0.58) | TACR1CA1CA2CA7CA9 | |
| SCHEMBL9677926 | 0.82 | TACR1 (0.66) | TACR1CA1CA2CA7CA9 | |
| SCHEMBL7421010 | 0.82 | TACR1 (0.66) | TACR1CA1CA2CA7CA9 | |
| SCHEMBL7332866 | 0.82 | TACR1 (0.66) | TACR1CA1CA2CA7CA9 | |
| SCHEMBL7095981 | 0.82 | TACR1 (0.75) | TACR1CA1CA2CA7CA9 | |
| SCHEMBL9569155 | 0.81 | TACR1 (0.54) | TACR1CA1CA2CA7CA9 | |
| SCHEMBL8030875 | 0.81 | CA1 (0.51) | TACR1CA1CA2CA7CA9 | |
| SCHEMBL22918182 | 0.80 | KMT2A (0.56) | TACR1CA1CA2CA7CA9 | |
| SCHEMBL8059580 | 0.80 | KMT2A (0.56) | TACR1CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383859-B2 | Methods of preparing primary, secondary and tertiary carbinamine compounds in the presence of ammonia | THADANI AVINASH N (CA) | 2013-02-26 | — | — | US | disclosed |
| US-8383859-B2 | Methods of preparing primary, secondary and tertiary carbinamine compounds in the presence of ammonia | THADANI AVINASH N (CA) | 2013-02-26 | — | — | US | disclosed |
| US-8383859-B2 | Methods of preparing primary, secondary and tertiary carbinamine compounds in the presence of ammonia | THADANI AVINASH N (CA) | 2013-02-26 | — | — | US | disclosed |
| US-8350047-B2 | Methods of preparing secondary carbinamine compounds with boronic acids | THADANI AVINASH N (CA) | 2013-01-08 | — | — | US | disclosed |
| US-8350047-B2 | Methods of preparing secondary carbinamine compounds with boronic acids | THADANI AVINASH N (CA) | 2013-01-08 | — | — | US | disclosed |
| US-20100298572-A1 | METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS | PANASONIC CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100298572-A1 | METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS | PANASONIC CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100174090-A1 | METHODS OF PREPARING PRIMARY, SECONDARY AND TERTIARY CARBINAMINE COMPOUNDS IN THE PRESENCE OF AMMONIA | THADANI AVINASH N | 2010-07-08 | — | — | US | disclosed |
| US-20100174090-A1 | METHODS OF PREPARING PRIMARY, SECONDARY AND TERTIARY CARBINAMINE COMPOUNDS IN THE PRESENCE OF AMMONIA | THADANI AVINASH N | 2010-07-08 | — | — | US | disclosed |
| WO-2008119161-A1 | METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119162-A1 | METHODS OF PREPARING PRIMARY, SECONDARY AND TERTIARY CARBINAMINE COMPOUNDS IN THE PRESENCE OF AMMONIA | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174090-A1 | METHODS OF PREPARING PRIMARY, SECONDARY AND TERTIARY CARBINAMINE COMPOUNDS IN THE PRESENCE OF AMMONIA | HNMT, AADAT, DAO | TACR1 1284/4885CA1 192/4885CA2 146/4885 |
| US-20100298572-A1 | METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS | C9, BCAT2, SLC1A5 | TACR1 487/4885CA1 122/4885CA2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.